Investor Relations: Jim Evans, Chief Financial Officer
Chris Martin, Director of Communications
Stephanie Ashe, Continuum Health Communications
Salt Lake City, December 10, 2012 – Myriad Genetics (NASDAQ: MYGN) announced today that Myriad RBM, a wholly owned subsidiary of Myriad Genetics, has entered into a research collaboration with Sanofi, a global and diversified healthcare leader, and Population Health Research Institute (PHRI) at Hamilton Health Sciences and McMaster University. Through this collaboration, Myriad RBM will perform protein biomarker research for the Outcome Reduction with Initial Glargine Intervention (ORIGIN) study, the world’s longest and largest randomized clinical trial in pre- and early diabetes. The relationship between the biomarker results and clinical outcomes will be analyzed by investigators at PHRI.
As part of the agreement, Myriad RBM will analyze over 8,000 serum samples collected in the ORIGIN study using its DiscoveryMAP® 250+ quantitative immunoassay panel. Sanofi conceived of the application of Myriad RBM’s technology to ORIGIN with a goal of identifying biomarker profiles that may optimize treatment and improve patient care.
“We are pleased to be partnering with Sanofi and PHRI, world leaders in diabetes research, on this critical study,” said Craig Benson, President of Myriad RBM. “We believe this collaboration will result in better care for millions of patients with diabetes; a global epidemic that remains a critical unmet medical need.”
Funded by Sanofi and directed and managed by PHRI, ORIGIN is a unique, six-year landmark cardiovascular (CV) outcomes trial, that evaluated Lantus® (insulin glargine) versus standard care in over 12,500 individuals at high CV risk with pre-diabetes or early type 2 diabetes mellitus. Spanning 40 countries worldwide, it was the world’s longest and largest randomized clinical trial of its type in this population.
“This biomarker project using DiscoveryMAP is a logical extension of the landmark ORIGIN study,” said Dr. Matt McQueen, Research Laboratory Director, PHRI. “The measurement of hundreds of relevant proteins in metabolic, inflammatory and other important pathways has the potential to improve treatment protocols for diabetes.”
This collaboration could represent up to $10 million in companion diagnostic service revenue for Myriad over the next two fiscal years. Additionally, this agreement was contemplated in the Company’s Companion Diagnostic Service revenue revised guidance for fiscal 2013 which was previously communicated on November 5, 2012.
About Myriad RBM
Myriad RBM’s biomarker discovery platform provides clinical researchers, physicians and healthcare providers with reproducible, quantitative, multiplexed data for hundreds of proteins to advance drug development and patient care. The company’s proprietary Multi Analyte Profiling (MAP) technology offers pre-clinical and clinical researchers broad, cost-effective analyses of multiple proteins from a single, small sample volume. MAP technology also supports Myriad RBM’s drive to develop companion diagnostics in areas of unmet medical need such as neuropsychiatry, nephrology, and immunology. Myriad RBM is a wholly owned subsidiary of Myriad Genetics. More information about Myriad RBM is located at www.myriadrbm.com.
About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patients’ lives through the discovery and commercialization of transformative tests to assess a person’s risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad’s portfolio of molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a commitment to improving an individual’s decision making process for monitoring and treating disease. Myriad is focused on strategic directives to introduce new products, including companion diagnostics, as well as expanding internationally. For more information on how Myriad is making a difference, please visit the Company’s website: www.myriad.com
Myriad, the Myriad logo, Myriad RBM, DiscoveryMAP are trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and foreign countries. MYGN-G